The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival
- PMID: 22013483
- PMCID: PMC3195678
- DOI: 10.1155/2011/695834
The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival
Abstract
B7-H4 is one of the most recently identified members of B7 superfamily of costimulatory molecules serving as an inhibitory modulator of T-cell response. B7-H4 is broadly expressed in human peripheral tissues and inducibly expressed in immune cells. The expression of B7-H4 has been observed in various types of human cancer tissues, and its soluble form has been detected in blood samples from cancer patients. However, its precise physiological role is still elusive, as its receptor has not been identified and the expression levels are not consistent. This paper summarizes the pertinent data on the inhibitory role of B7-H4 in antitumor immunity and its association with cancer progression and survival in human patients. The paper also discusses the clinical significance of investigating B7-H4 as potential markers for cancer diagnosis and prognosis, and as therapeutic targets.
Similar articles
-
B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.Cancer Immunol Res. 2015 Feb;3(2):184-95. doi: 10.1158/2326-6066.CIR-14-0113. Epub 2014 Dec 19. Cancer Immunol Res. 2015. PMID: 25527357
-
Potential targeting of B7-H4 for the treatment of cancer.Immunol Rev. 2017 Mar;276(1):40-51. doi: 10.1111/imr.12530. Immunol Rev. 2017. PMID: 28258701 Free PMC article. Review.
-
B7-H3 and B7-H4 expression in phyllodes tumors of the breast detected by RNA in situ hybridization and immunohistochemistry: Association with clinicopathological features and T-cell infiltration.Tumour Biol. 2018 Nov;40(11):1010428318815032. doi: 10.1177/1010428318815032. Tumour Biol. 2018. PMID: 30486739
-
Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.World J Surg. 2011 Sep;35(9):2051-7. doi: 10.1007/s00268-011-1186-4. World J Surg. 2011. PMID: 21748517
-
Could B7-H4 serve as a target to activate anti-cancer immunity?Int Immunopharmacol. 2016 Sep;38:97-103. doi: 10.1016/j.intimp.2016.05.020. Epub 2016 Jun 1. Int Immunopharmacol. 2016. PMID: 27258187 Review.
Cited by
-
The prognostic value of B7-H4 in pancreatic cancer: Systematic review and meta-analysis.Medicine (Baltimore). 2018 Mar;97(12):e0088. doi: 10.1097/MD.0000000000010088. Medicine (Baltimore). 2018. PMID: 29561406 Free PMC article.
-
Inhibitory receptors as targets for cancer immunotherapy.Eur J Immunol. 2015 Jul;45(7):1892-905. doi: 10.1002/eji.201344413. Eur J Immunol. 2015. PMID: 26018646 Free PMC article. Review.
-
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.J Clin Med. 2019 Oct 1;8(10):1566. doi: 10.3390/jcm8101566. J Clin Med. 2019. PMID: 31581482 Free PMC article.
-
The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.Immune Netw. 2014 Dec;14(6):265-76. doi: 10.4110/in.2014.14.6.265. Epub 2014 Dec 22. Immune Netw. 2014. PMID: 25550693 Free PMC article. Review.
-
B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer.Cancer Cell Int. 2022 Apr 11;22(1):147. doi: 10.1186/s12935-022-02567-1. Cancer Cell Int. 2022. PMID: 35410218 Free PMC article.
References
-
- Prasad DVR, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003;18(6):863–873. - PubMed
-
- Sica GL, Choi IH, Zhu G, et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003;18(6):849–861. - PubMed
-
- Choi IH, Zhu G, Sica GL, et al. Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. Journal of Immunology. 2003;171(9):4650–4654. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials